Last reviewed · How we verify
Naproxen sodium ER (BAYH6689)
Naproxen sodium ER (BAYH6689) is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Bayer. It is currently in Phase 3 development for Chronic pain management, Osteoarthritis, Rheumatoid arthritis.
Naproxen sodium ER is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.
Naproxen sodium ER is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Chronic pain management, Osteoarthritis, Rheumatoid arthritis.
At a glance
| Generic name | Naproxen sodium ER (BAYH6689) |
|---|---|
| Sponsor | Bayer |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Naproxen blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. The extended-release formulation provides sustained drug delivery over time, allowing for less frequent dosing while maintaining therapeutic levels. This mechanism makes it effective for chronic pain and inflammatory conditions.
Approved indications
- Chronic pain management
- Osteoarthritis
- Rheumatoid arthritis
Common side effects
- Gastrointestinal upset / dyspepsia
- Nausea
- Headache
- Dizziness
- Cardiovascular events (with chronic use)
- Renal impairment (with chronic use)
Key clinical trials
- Actual Use Trial of Naproxen Sodium (PHASE3)
- Self Selection Trial of Naproxen Sodium (PHASE3)
- Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain. (PHASE3)
- Naproxen Sodium Extended-Release Actual Use Study (PHASE3)
- Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium (PHASE3)
- Naproxen Sodium ER Pharmacokinetic Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naproxen sodium ER (BAYH6689) CI brief — competitive landscape report
- Naproxen sodium ER (BAYH6689) updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Naproxen sodium ER (BAYH6689)
What is Naproxen sodium ER (BAYH6689)?
How does Naproxen sodium ER (BAYH6689) work?
What is Naproxen sodium ER (BAYH6689) used for?
Who makes Naproxen sodium ER (BAYH6689)?
What drug class is Naproxen sodium ER (BAYH6689) in?
What development phase is Naproxen sodium ER (BAYH6689) in?
What are the side effects of Naproxen sodium ER (BAYH6689)?
What does Naproxen sodium ER (BAYH6689) target?
Related
- Drug class: All Nonsteroidal anti-inflammatory drug (NSAID) drugs
- Target: All drugs targeting COX-1 and COX-2
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Pain Management / Rheumatology
- Indication: Drugs for Chronic pain management
- Indication: Drugs for Osteoarthritis
- Indication: Drugs for Rheumatoid arthritis
- Compare: Naproxen sodium ER (BAYH6689) vs similar drugs
- Pricing: Naproxen sodium ER (BAYH6689) cost, discount & access